BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Retevmo (Selpercatinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Retevmo (Selpercatinib)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04268550-2209@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Retevmo (Selpercatinib): Phase 2 readout est. (NCT04268550)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cel
 l Lung Cancer (A LUNG-MAP Treatment Trial)\nEstimated primary completion: 
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/selp
 ercatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04268550
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146893-2209@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Retevmo (Selpercatinib): Phase 1 readout est. (NCT07146893)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 1.\nStudy: Feasibility Study fo
 r Repurposing RET Inhibitors\nEstimated primary completion: 23 February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/selpercatinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0714689
 3
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2209@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Retevmo (Selpercatinib): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 2.\nStudy: The Drug Rediscovery
  Protocol (DRUP Trial)\nEstimated primary completion: September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/selpercatinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04759911-2209@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Retevmo (Selpercatinib): Phase 2 readout est. (NCT04759911)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 2.\nStudy: Selpercatinib Before
  Surgery for the Treatment of RET-Altered Thyroid Cancer\nEstimated primar
 y completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/selpercatinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04759911
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-2209@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retevmo (Selpercatinib): Phase 4 readout est. (NCT07010393)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 4.\nStudy: Genotype-Driven Neoa
 djuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort S
 tudy\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/selpercatinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822880-2209@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Retevmo (Selpercatinib): Phase 4 readout est. (NCT07822880)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 4\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of Selpercatinib (LY3527723) in Participants With Rearran
 ged During Transfection (RET)-Altered Cancers in India\nEstimated primary 
 completion: October 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/selpercatinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07822880
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06458036-2209@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Retevmo (Selpercatinib): Phase 2 readout est. (NCT06458036)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 2.\nStudy: Selpercatinib Pre-RA
 I in Patients With RET Fusion Thyroid Cancer (RAISE)\nEstimated primary co
 mpletion: 1 November 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/selpercatinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06458036
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
